Equities

Alembic Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
ALEMBICLTD:NSI

Alembic Ltd

Actions
Real EstateReal Estate Investment and Services
  • Price (INR)97.85
  • Today's Change-0.16 / -0.16%
  • Shares traded15.18k
  • 1 Year change-27.14%
  • Beta1.2779
Data delayed at least 15 minutes, as of Oct 17 2025 04:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Alembic Limited is an India-based company engaged in the business of development, manufacturing, and marketing of pharmaceutical products. The Company's segments include the Active Pharmaceutical Ingredients Business and the Real Estate Business. The Active Pharmaceutical Ingredients Business is engaged in the manufacturing and marketing of fermentation and chemistry-based active pharmaceutical ingredients (API). The Real Estate Business is engaged in the construction of residential and commercial real estate projects and project management and marketing consultancy. The Company provides certain commercial properties on a lease basis to various tenants. The Company is also engaged in research and development activities in Vadodara. It is also engaged in power generation through co-generation.

  • Revenue in INR (TTM)2.21bn
  • Net income in INR3.16bn
  • Incorporated1907
  • Employees256.00
More ▼

Institutional shareholders

0.99%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 04 Sep 20251.94m0.76%
The Vanguard Group, Inc.as of 31 Aug 2025263.18k0.10%
American Century Investment Management, Inc.as of 04 Sep 2025161.25k0.06%
Dimensional Fund Advisors Ltd.as of 04 Sep 202592.40k0.04%
SSgA Funds Management, Inc.as of 04 Sep 202557.78k0.02%
DFA Australia Ltd.as of 31 Aug 202521.78k0.01%
Motilal Oswal Asset Management Co. Ltd.as of 31 Aug 2025169.000.00%
More ▼
Data from 30 Jun 2025 - 15 Sep 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.